Anileridine

Anileridine2DCSD.svg

Synthetic opioid analgesic

Anileridine is a synthetic opioid analgesic that is structurally related to pethidine (meperidine). It was developed in the 1950s by the pharmaceutical company Merck & Co. as a potential alternative to pethidine with a better side effect profile.

Pharmacology

Anileridine works by binding to the opioid receptors in the central nervous system, which leads to the inhibition of pain signals. It is primarily used for the management of moderate to severe pain. The drug has a similar mechanism of action to other opioids, such as morphine and fentanyl, but with some differences in its pharmacokinetic properties.

Medical Uses

Anileridine is indicated for the relief of moderate to severe pain. It is often used in a hospital setting for postoperative pain management and in patients who require continuous pain relief. The drug can be administered orally or via intravenous injection.

Side Effects

Common side effects of anileridine include nausea, vomiting, dizziness, and constipation. Like other opioids, it has the potential for abuse and dependence. Overdose can lead to severe respiratory depression and death.

Legal Status

Anileridine is classified as a controlled substance in many countries due to its potential for abuse and dependence. In the United States, it is listed as a Schedule II controlled substance under the Controlled Substances Act.

History

Anileridine was first synthesized in the 1950s by Merck & Co. It was introduced as a potential alternative to pethidine, with the aim of providing effective pain relief with fewer side effects. However, its use has declined over the years with the development of newer analgesics.

See Also

• Opioid
• Analgesic
• Pethidine
• Morphine
• Fentanyl